年轻套细胞淋巴瘤首次复发难治患者的结局:MANTLE-FIRST研究结果
MANTLE-FIRST研究纳入261例接受含大剂量阿糖胞苷一线方案后首次复发难治的套细胞淋巴瘤患者,比较二线方案R-B、R-BAC、伊布替尼及其他方案的结局。调整年龄和早期/晚期进展后,R-BAC完全缓解率63%显著高于对照;伊布替尼和R-BAC中位PFS-2分别为24和25个月,优于R-B的13个月和其他的7个月。早期进展患者中伊布替尼死亡风险低于对照,晚期进展患者中伊布替尼与苯达莫司汀为基础方案无显著差异。
要点
- 261例首次复发难治套细胞淋巴瘤患者中,二线方案以R-BAC(29%)和R-B(21%)最常见。
- 调整年龄和早期/晚期进展后,R-BAC完全缓解率63%显著高于对照。
- 早期进展患者中伊布替尼死亡风险低于对照(HR 2.41、2.17、2.78分别对应R-B、其他、R-BAC)。
核心结论
- 在首次复发难治的年轻套细胞淋巴瘤患者中,伊布替尼与早期进展患者的结局改善相关。
研究设计与样本
- MANTLE-FIRST研究纳入261例接受含大剂量阿糖胞苷标准方案一线治疗后首次复发难治的套细胞淋巴瘤患者。
- 从挽救治疗起估算总生存(OS-2)和无进展生存(PFS-2),以24个月为阈值定义早期或晚期进展。
- 二线方案包括利妥昔单抗-苯达莫司汀(R-B,21%)、R-B联合阿糖胞苷(R-BAC,29%)、伊布替尼(19%)和其他(31%)。
主要发现
- 调整年龄和早期/晚期进展后,R-BAC组完全缓解率63%显著高于对照。
- 伊布替尼和R-BAC中位PFS-2分别为24和25个月,R-B为13个月,其他为7个月。
- 早期进展患者(n=127)中,伊布替尼死亡风险低于对照:R-B的HR为2.41,其他的HR为2.17,R-BAC的HR为2.78。
- 晚期进展患者(n=134)中,伊布替尼与苯达莫司汀为基础方案之间无显著差异。
关键数值与推荐
- 以24个月为阈值定义早期或晚期进展。
- R-BAC完全缓解率63%显著高于对照。
- 伊布替尼和R-BAC中位PFS-2分别为24和25个月,R-B为13个月,其他为7个月。
- 早期进展患者中伊布替尼死亡风险低于对照:R-B的HR为2.41,其他的HR为2.17,R-BAC的HR为2.78。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with mantle cell lymphoma (MCL) that fail induction treatment represent a difficult-to-treat population, where no standard therapy exists. We evaluated outcomes in patients with first relapsed-refractory (r/r) MCL after upfront high dose cytarabine including standard regimens. Overall survival (OS-2) and progression-free survival (PFS-2) were estimated from the time of salvage therapy. The previously described threshold of 24 months was used to define patients as early- or late-progressors (POD). Overall, 261 r/r MCL patients were included. Second-line regimens consisted of rituximab-bendamustine (R-B, 21%), R-B and cytarabine (R-BAC, 29%), ibrutinib (19%), and others (31%). The four groups were balanced in terms of clinicopathological features. Adjusting for age and early/late-POD, patients treated with R-BAC had significantly higher complete remission (63%) than comparators. Overall, Ibrutinib and R-BAC were associated with improved median PFS-2 [24 and 25 months, respectively], compared to R-B (13) or others (7). In patients with early-POD (n = 127), ibrutinib was associated with inferior risk of death than comparators (HR 2.41 for R-B, 2.17 for others, 2.78 for R-BAC). In patients with late-POD (n = 134), no significant differences were observed between ibrutinib and bendamustine-based treatments. Ibrutinib was associated with improved outcome in early-POD patients.
引用
- Visco C, Di Rocco A, Evangelista A, et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia. 2020. PMID: 32782382. doi:10.1038/s41375-020-01013-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。